---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086275"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:11:50.292644+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precigen reports $19.5M cash, $32.9M impairment, $30M offering, >20% workforce cut

## Summary
- Preliminary cash $19.5M at June 30, 2024; non-cash impairment charges ~$32.9M and severance ~$3.0M in Q2/Q3.
- Strategic pivot to PRGN-2012 gene therapy; rolling BLA submission expected H2 2024; ActoBio subsidiary shutdown.
- Commences $30M underwritten public offering (plus $4.5M option); expects net proceeds plus cash to fund ops into early 2025.
- Workforce reduced >20%; PRGN-2009 non-NCI sites paused; UltraCAR-T programs paused except PRGN-3006; preclinical halted.
- PRGN-2012 confirmatory trial initiated; commercial readiness led by new CCO; revenue not reported (pre-revenue stage).

## SEC filing metadata
- accession: 0001104659-24-086275
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000110465924086275/0001104659-24-086275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000110465924086275/tm2418396d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086275
- JSON: https://secwatch.observer/filing/0001104659-24-086275.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.